Navigation Links
Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
Date:3/11/2011

ients greater precision in their efforts to fine tune their glucose control. Patients treated with insulin pumps represent a significant portion of the market, manage their disease aggressively, and are early adopters of new treatments and technologies.
  • Halozyme's two Phase 2 clinical studies that compare treatment with an insulin analog alone to Analog-PH20 for twelve weeks each completed patient enrollment this past January. Results from these two studies will be available to Halozyme internally during the third quarter of 2011.
  • Roche completed patient enrollment of its Phase 3 registration study for Herceptin® SC (trastuzumab subcutaneous) in December for the treatment of HER2-positive breast cancer and has stated it expects to have results from this study by the end of 2011. In February 2011, Roche began patient dosing of the Phase 3 MabThera® SC (rituximab subcutaneous) clinical trial in patients with follicular non-Hodgkin's lymphoma. Roche has stated it expects to file for the approval of Herceptin SC and MabThera SC in the EU during 2012.
  • Baxter completed its Phase 3 clinical trial of HyQ, immunoglobulin with rHuPH20, at the end of 2010. Baxter has stated it plans to submit a BLA filing during the second half of 2011 and to launch the product in 2012. The worldwide market for immunoglobulin totals approximately $6 billion and Baxter commands a sizeable share of the market.

  • Fourth Quarter and Year End 2010 Financial ResultsThe net loss for the fourth quarter of 2010 was $16.9 million, or $0.17 per share, compared with a net loss for the fourth quarter of 2009 of $12.7 million, or $0.14 per share. The net loss for the year ended December 31, 2010 was $53.2 million, or $0.56 per share, compared to a net loss of $58.4 million, or $0.67 per share, for the year 2009.

  • Revenue for the fourth quarter of 2010 was $3.6 million, compared to $6.4 million for the
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Halozyme Therapeutics to Host Fourth Quarter and 2010 Financial Results Conference Call on March 11
    2. Halozyme Therapeutics to Present at J.P. Morgan Healthcare Conference on January 12
    3. Halozyme Therapeutics Realigns Management
    4. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
    5. Halozyme Therapeutics Announces Implementation of Development Focused Strategy
    6. Halozyme Therapeutics to Host Analyst Meeting on October 14 in New York
    7. Halozyme Therapeutics Announces Public Offering of Common Stock
    8. Halozyme Provides HYLENEX® Product Reintroduction Update
    9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
    10. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
    11. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/3/2015)... India , September 3, 2015 ... Metallic compounds, Organosulfurs, Organic acids, Phenolics, and Others) and ... & beverage, Paints & coatings, and Others) - Global ... and segments the Biocides Market with an analysis and ... as value. Browse   88 tables ...
    (Date:9/3/2015)... and REHOVOT, Israel, Sept. 3, 2015 ... and developing innovative therapies for ear, nose, and throat ... Company,s Newport Gateway office complex to be the location ... the move by end of September and will have ... U.S. Headquarters: OticPharma, Inc. 19900 MacArthur Blvd., ...
    (Date:9/2/2015)... , Sept. 2, 2015 Balloon angioplasty ... obstructed blood vessels. This report is on global ... of the market. The report comprises an elaborate ... provides overall information of various segments and sub-segments ... the overall information and data analysis of the ...
    Breaking Medicine Technology:Biocides Market Worth 10.6 Billion USD by 2020 2Biocides Market Worth 10.6 Billion USD by 2020 3Biocides Market Worth 10.6 Billion USD by 2020 4Biocides Market Worth 10.6 Billion USD by 2020 5OticPharma Establishes U.S. Headquarters in Orange County, California 2Angioplasty Balloons Market: : Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Angioplasty Balloons Market: : Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3
    (Date:9/3/2015)... ... September 03, 2015 , ... ... providers, has been retained to lead a national chief executive officer ... search firms in the healthcare industry, B. E. Smith has recently placed more ...
    (Date:9/3/2015)... ... September 03, 2015 , ... Dr. Robert Winchell has been appointed director ... Acute Care at NewYork-Presbyterian/Weill Cornell Medical Center, effective July 27. He will serve on ... expert in care for the critically injured and the development, design and operations of ...
    (Date:9/3/2015)... ... September 03, 2015 , ... According to an Oncology ... test that may help patients with oropharyngeal cancer (oral cancer) to be successfully diagnosed ... are often caused by HPV infections, which have a high rate of success in ...
    (Date:9/3/2015)... ... September 03, 2015 , ... Global Vision , the ... will be spotlighting its award-winning print and artwork inspection solutions, ScanProof and ... and 17 at the Olympia London, booth #F33 , Be the first to get ...
    (Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... Act (ACA) triggering cost increases for fully insured employer-sponsored health insurance plans, more ... employers (1,000+ employees), according to data released from the 2014 United Benefit Advisors ...
    Breaking Medicine News(10 mins):Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 2Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 4Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 5Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 2Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 3Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4
    ... The experts reveal that lot more funds are needed from ... deaths of children under five by two-thirds.// ,Five ... experts, whose paper is one of the series of papers ... high-level meeting hosted by the journal, UNICEF and the Norwegian ...
    ... drug extensively used to treat acne can cause depression. ... animals.// ,Recently, the drug- Roaccutane, which effectively ... severe side-effects like suicidal behaviour. Though the packaging of ... occurrence of such side-effects is not known.,It has not ...
    ... an anti-cancer drug called Biomab-EGFR and had Shah Rukh Khan ... told reporters that the drug would be priced at 40 ... "Today we join the exclusive league of MAb developers worldwide. ... she added. She also told the drug was undergoing regulatory ...
    ... and Kashmir has a new problem to contend with now ... there are 745 such cases in the insurgency-hit state, unofficial ... there were only two cases reported, writes Grassroots Features. The ... the infection rate among the high-risk groups (STD-infected) at 0.95 ...
    ... arm in a motorcycle accident. She has become the first woman to ... own nerves. ,She talked about how she used it ... able to eat in a conventional way since her accident of over ... me.” ,Very often patients fitted with high-tech prosthetic limbs ...
    ... A new web site at the University of California, ... will enable people from around the world// to self-report ... other cholesterol drugs. ,“This line of research ... heart disease and cholesterol are familiar with the benefits ...
    Cached Medicine News:Health News:Child death reduction needs five times more funds 2Health News:Acne drug may cause depression 2Health News:Kashmir Grapples with Growing AIDS 2Health News:Kashmir Grapples with Growing AIDS 3Health News:Bionic Women –No longer the Stuff of Science Fictio 2Health News:Patients Can Report Statins' Adverse Effects on New Web Site 2
    ... Coagulation tubes contain a buffered ... available with a citrate concentration ... 0.129 mol/l (3.8%). The mixing ... solution to 9 parts blood. ...
    ... Cross-match tubes are available ... serum tube contains a clotting ... cross-match tests where serum is ... EDTA cross-match tube is suitable ...
    Inquire...
    ... as either EDTA K2 or EDTA ... ions and therefore blocks the coagulation ... an EDTA anticoagulated blood sample are ... EDTA tubes are for the examination ...
    Medicine Products: